Noubar Afeyan, PhD
Noubar Afeyan, PhD, is co-founder of Flagship Pioneering. During his career as inventor, entrepreneur, and CEO, Noubar has co-founded and helped build over 40 life science and technology startups.
Prior to founding Flagship Pioneering, Noubar was the founder and CEO of PerSeptive Biosystems, a leader in bioinstrumentation that grew to $100 million in annual revenues. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation, he served as Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics.
In addition to Sana, Noubar serves on the boards of several public and private companies, including Moderna, where he is Chairman, and Rubius Therapeutics. He was a member of the founding team and director and investor in highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb), and Affinnova (acquired by AC Nielsen).
Noubar has written numerous scientific publications and is the inventor on more than 80 patents.
Noubar earned his BS in chemical engineering from McGill University and completed his PhD in biochemical engineering at Massachusetts Institute of Technology (MIT).